No benefit from pazopanib in advanced kidney cancer after surgery to remove metastases
The results of the ECOG-ACRIN Cancer Research Group's phase three trial, E2810, are being orally presented at the 2019 annual ...
Tag: cancer
NCI-MATCH trial finds the combination of dabrafenib and trametinib effective
Findings from Arm H show that in a heavily pre-treated cohort of 17 distinct tumor types -- several rare -- ...
Featured research findings from Nutrition 2019
Conference press materials now available Press materials are now available for Nutrition 2019, the flagship meeting of the American Society ...
POLO trial for advanced pancreatic cancer: a new standard of care
Olaparib doubled progression-free survival for patients with BRCA mutationsCredit: Robert Kozloff, UChicago Treatment with the drug olaparib significantly reduced the ...
Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers
Nivolumab plus ipilimumab meet primary endpoint of MD Anderson NEOSTAR Phase II trialCredit: MD Anderson Cancer Center CHICAGO - Neoadjuvant, ...
NRG Oncology trial sets new standard regimen for women with uterine carcinosarcomas
Results from the phase III NRG Oncology clinical trial GOG 0261 comparing paclitaxel plus carboplatin (PC) to paclitaxel plus ifosfamide ...
Suggested benefit in PCV chemoradiotherapy for both IDH-mutant WHO-defined molecular subgroups
Analyses of NRG Oncology/RTOG 9802 Suggests both IDH-mutant WHO-defined molecular subgroups of high-risk low-grade gliomas may benefit from the addition ...
Patients who received PBI without chemotherapy experienced less fatigue, slightly poorer cosmesis
Patients who received partial breast irradiation without chemotherapy experienced less fatigue, slightly poorer cosmesis on NRG Oncology trial Patient-reported outcome ...
Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer
Credit: Dana-Farber Cancer Institute After 3 years, 80% of men with metastatic hormone-sensitive prostate cancer who received enzalutamide along with ...
NRG oncology trial of metformin for non-small cell lung cancer
NRG oncology trial shows tolerability of metformin for non-small cell lung cancer, no improvement in survival outcomes between treatments Initial ...
NRG trial suggests total neoadjuvant therapy for locally advanced rectal cancer is safe
Initial experimental treatment arm results from NRG oncology trial suggests total neoadjuvant therapy for locally advanced rectal cancer is safe ...
Ribociclib plus hormone therapy extends survival for patients with premenopausal advanced hormone receptor-positive breast cancer
MD Anderson-led Phase III trial finds targeted therapy lowers risk of death, is well-toleratedCredit: MD Anderson Cancer Center ABSTRACT LBA1008 ...
ASCO: Finally, a tool to predict response to chemotherapy before bladder cancer surgery
Credit: University of Colorado Cancer Center University of Colorado Cancer Center led clinical trial data show that a predictive tool ...
A new way to predict complications after larynx cancer surgery
When the surgical wound doesn't heal right, it can send some patients back to the OR; a new technique tested ...
Radio-wave therapy proves effective against liver cancer cells
Left hand image: Patient with metastatic cancer affecting various organs receiving first AM RF EMF systemic targeted treatment. Blue arrows ...
Stand up to cancer-funded research to be presented at ASCO May 31-June 4 in Chicago
Immunotherapy, genetic testing, drug resistance, and machine learning are topics of presentations at meeting of American Society for Clinical OncologyCredit: ...
Early genome catastrophes can cause non-smoking lung cancer
Some teenagers harbor catastrophic changes to their genomes that can lead to lung cancer later on in life, even if ...
New research paves the way for safer leukemia treatments
An international team of researchers has discovered a new and much safer way to treat a type of leukaemia that ...
Pre-surgical immunotherapy shows promise in trial for patients with early stage lung cancer
Interim results of a large, multicenter trial to be presented at ASCO Annual Meeting For patients with operable non-small cell ...
Clinical calculator could spare breast cancer patients five years of unnecessary hormone therapy
New research confirms that an algorithm, called CTS5, can accurately identify patients who are at a significantly low risk of ...
